Clinical Trial Update: Study Evaluating TSE-424/Placebo/Raloxifene in Preventing Osteoporosis in Postmenopausal Women [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating TSE-424, placebo, and raloxifene for osteoporosis prevention in postmenopausal women has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Osteoporosis

Drugs mentioned

• Raloxifene (raloxifene)
• TSE-424

Snippet

Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer | Conditions: Osteoporosis | Phase 3 | Status: COMPLETED